Instituto de Investigación Biomédica de Salamanca - IBSAL

What Instituto de Investigación Biomédica de Salamanca - IBSAL does

IBSAL is a non-profit biomedical research institute founded in 2011 in Salamanca, Spain, legally constituted as Fundación de Investigación Biomédica de Salamanca. It was established through a tripartite partnership among the Junta de Castilla y León's Department of Health, the Universidad de Salamanca, and CSIC, and received accreditation from the Instituto de Salud Carlos III in 2014 as one of 35-36 accredited national biomedical research institutes and the only one in Castilla y León. The institute operates from within the Hospital Universitario de Salamanca complex, structurally enabling translation from bench to bedside.

The institute organizes research across six scientific areas—Cancer (22 groups), Cardiovascular/Renal/Respiratory (11 groups), Neurosciences (12 groups), Infectious/Inflammatory/Metabolic Diseases (19 groups), Gene and Cellular Therapy and Transplants (6 groups), and Primary Care/Public Health/Pharmacology (16 groups)—totaling 86 research groups. These groups are supported by 14 specialized scientific platforms covering biobanking, biostatistics, bioinformatics, biomarkers, biomodels/transgenesis, clinical trials (SCReN), viral vector production, proteomics, REDCap data capture, clinical epidemiology, cardiac imaging, experimental surgery, and medical device innovation (I.T.SAL). The institute also operates research management units, a Virtual Campus for training, and governance services including a transparency portal and complaints channel.

IBSAL's business model is non-commercial: it does not sell products or services and pricing is not applicable. The institute is funded through two principal streams: core public institutional funding from its founding partners (regional government, university, and CSIC) and competitive research grants from regional, national, and international agencies including the Instituto de Salud Carlos III and PERTE para la Salud de Vanguardia. Its outputs are distributed through scientific publications, clinical implementation within the partner hospital, technology transfer, and citizen engagement. The current scientific director is Luis García Ortiz, appointed in 2023, who oversees ongoing consolidation of the foundation's research mission.

Name

Instituto de Investigación Biomédica de Salamanca - IBSAL

Legal name

Fundación de Investigación Biomédica de Salamanca

Website

https://ibsal.es

Company type

Private

Founded year

2011

Operating status

Operating

Short description

IBSAL is a Spanish non-profit biomedical research institute in Salamanca accredited by the Instituto de Salud Carlos III. It integrates basic, clinical, epidemiological, and health services research across six scientific areas with 86 research groups and 14 specialized platforms.

Ownership category

akta.pro rank

Headquarters

HQ city

Salamanca

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Public Institutional Funding: Core institutional funding from founding and participating public institutions including the Junta de Castilla y León (Consejería de Sanidad), Universidad de Salamanca, and CSIC, forming the primary financial foundation for IBSAL's operations.
2. Competitive Research Grants: Externally funded research projects through regional, national, and international competitive grant programs, including calls from the Instituto de Salud Carlos III, the PERTE para la Salud de Vanguardia, and other public funding agencies.

Distribution channels3 records

Marketing channels8 records

Core offering

IBSAL is a non-profit biomedical research institute that integrates basic, clinical, epidemiological, and health services research through 86 research groups and 14 specialized scientific platforms. It operates from within the Hospital Universitario de Salamanca complex, facilitating translational research from bench to bedside across six scientific areas including cancer, cardiovascular, neurosciences, infectious diseases, gene and cell therapy, and public health.

Product overview

IBSAL is a biomedical research institute structured as a platform-based research ecosystem. It operates multiple specialized research platforms (Biobank, Biostatistics, Bioinformatics, Biomarkers, Biomodels/Transgenesis, Clinical Trials/SCReN, Clinical Epidemiology, Cardiac Imaging, I.T.SAL Innovation, Viral Vector Production, Proteomics, Experimental Surgery, and REDCap) that support six main research areas: Cancer (22 groups), Cardiovascular/Renal/Respiratory (11 groups), Neurosciences (12 groups), Infectious/Inflammatory/Metabolic Diseases (19 groups), Gene/Cell Therapy and Transplants (6 groups), and Primary Care/Public Health/Pharmacology (16 groups). The institute also provides research management services, training through its Virtual Campus, and governance tools including a complaints channel and transparency portal.

Differentiator

Problem solved

Functional benefit

Brands

• I.T.SAL: Innovation platform for medical devices and health products developed by IBSAL researchers.
• Campus Virtual IBSAL
• RMN Biomolecular

Products and services

• Biobank Platform (Plataforma de Biobancos) Centralized biobanking infrastructure for biological sample storage and management supporting translational research across IBSAL's 86 research groups.
• Bioinformatics Platform (Plataforma de Bioinformática) Computational biology and data analytics platform supporting omics data processing and interpretation for biomedical researchers.
• Biostatistics Platform (Plataforma de Bioestadística) Statistical design and analysis services supporting clinical and translational research studies at IBSAL.
• Biomarkers Platform (Plataforma de Biomarcadores) Discovery and validation platform for disease biomarkers in support of precision medicine research.
• Biomodels/Transgenesis Platform (Plataforma de Biomodelos) Genetically modified animal model production service for preclinical research use across IBSAL's research areas.
• Clinical Trials Platform (Plataforma de Ensayos Clínicos / SCReN) National clinical trial coordination and management infrastructure supporting multicenter clinical studies (SCReN platform).
• Clinical Epidemiology Platform (Plataforma de Epidemiología Clínica y Metodología) Clinical epidemiology research methodology and study design support for translational research.
• Cardiac Imaging Platform (Plataforma de Imagen Cardiaca) Advanced cardiac imaging technologies and infrastructure supporting cardiovascular research.
• Innovation and Medical Device Platform (I.T.SAL) Medical device innovation and product development support services for IBSAL researchers and partners.
• Viral Vector Production and Molecular Cloning Platform (Plataforma de Producción de Vectores Virales y Clonaje Molecular) Viral vector manufacturing and molecular cloning services for gene therapy research applications.
• Proteomics Platform (Plataforma de Proteómica) Protein analysis and proteomics characterization services for biomarker discovery and biomedical research.
• Experimental Surgery Platform (Plataforma de Quirófano Experimental IBSAL-USAL) Surgical research facility for preclinical surgical interventions, jointly operated with the Universidad de Salamanca.
• REDCap Platform (Plataforma REDCap) Electronic data capture and clinical trial data management system for research studies.
• Virtual Campus (Campus Virtual IBSAL) Online learning platform offering training courses for researchers, staff, and the broader biomedical community.
• Research Portal (Portal de Investigación) Internal research portal for managing research projects, patents, scientific publications, and output tracking for the institute's 86 research groups.
• Scientific Support Unit (Unidad de Apoyo Científico) Unit providing scientific support services for research activities across IBSAL's research groups.
• Technical Management Unit (Unidad Técnica de Gestión) Unit providing technical and administrative management services for research projects, including grant administration and regulatory compliance.

Quantifiable outcome

• 86 research groups across 6 scientific areas supported by 14 specialized platforms

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature13 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Instituto de Biología Funcional y Genómica (IBFG)coreStrategic or Co-development Partner · 3 July 2026IBFG is a joint CSIC-Universidad de Salamanca research center that actively participates in IBSAL research programs. Researcher Ángeles Almeida leads molecular neurobiology research through both IBFG and IBSAL.
• Hospital Universitario Quirónsalud de MadridminorStrategic or Co-development Partner · 4 June 2026Clinical partner that referred a patient with a pathological Cdh1 mutation for collaborative study, leading to joint research on neurodevelopment and growth disorders published in Communications Biology.
• European Healthcare and Research Institutions (France, Germany, Madrid, País Vasco)minorStrategic or Co-development Partner · 4 June 2026International research collaborators in specialized neuroscience, magnetic resonance imaging, pathological anatomy, and super-resolution microscopy contributing to multidisciplinary studies on neurodevelopment.
• Citizen Associations (Fundaneed, AFIBROSAL, LGTB+ Iguales, ASPACE, Retina Salamanca, ASDACE)minorStrategic or Co-development Partner · 4 June 2026Citizen associations collaborating with IBSAL on science outreach and public engagement activities as part of the institute's citizen science and open science initiatives.
• Consejo Superior de Investigaciones Científicas (CSIC)coreStrategic or Co-development Partner · 1 February 2012CSIC joined as an institutional partner in February 2012, contributing research groups through joint centers such as the Instituto de Biología Funcional y Genómica (IBFG).
• Junta de Castilla y León (Consejería de Sanidad)coreStrategic or Co-development Partner · 21 March 2011Founding institutional partner through the Castilla y León regional government's health department. Signed the founding convention on March 21, 2011 establishing IBSAL as the regional biomedical research institute.
• Universidad de Salamanca (USAL)coreStrategic or Co-development Partner · 21 March 2011Founding academic partner and primary university affiliated with IBSAL. Contributes research groups from across its faculties and hosts the IBFG joint center (CSIC-USAL) within IBSAL's research ecosystem.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer: Hospital Clinic Barcelona-affiliated ISCIII-accredited biomedical research institute, structured around multiple research areas with strong translational orientation — directly comparable in mission and operating model to IBSAL.
• Vall d'Hebron Institut de Recerca (VHIR): Hospital-integrated ISCIII-accredited biomedical research institute affiliated with Hospital Universitari Vall d'Hebron in Barcelona, with a comparable translational, multi-area research mandate across hospital-based groups.
• IIS La Fe - Instituto de Investigación Sanitaria La Fe: Valencia hospital-integrated ISCIII-accredited biomedical research institute with a comparable translational mandate anchored in a university hospital complex.
• CiMUS - Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (USC): Santiago de Compostela biomedical research center with a similar translational research focus, multi-area research groups, and shared platform infrastructure.
• IBIMA - Instituto de Investigación Biomédica de Málaga: Andalusian ISCIII-accredited biomedical research institute with a multi-area structure and regional public-health university hospital partnership, comparable in scale and mission.
• CIMA - Centro de Investigación Médica Aplicada (Universidad de Navarra): University-affiliated biomedical research center organized around translational programs in oncology, neuroscience, cardiovascular, and immunology — comparable in academic-hospital integration.
• IRB Barcelona - Institute for Research in Biomedicine: Catalonia-based biomedical research institute focused on translational science across multiple disease areas, with shared scientific platforms and an analogous multi-group research structure.
• IDIBELL - Institut d'Investigació Biomèdica de Bellvitge: Hospital Universitari de Bellvitge-affiliated ISCIII-accredited biomedical research institute with hospital-integrated translational research groups spanning cancer, neurosciences, and infectious diseases.

Broad incumbents

• CNIC - Centro Nacional de Investigaciones Cardiovasculares: Spain's national cardiovascular research center with substantially larger scale, broader national remit, and higher international visibility; overlaps IBSAL's cardiovascular research area at a much broader portfolio level.
• CNIO - Centro Nacional de Investigaciones Oncológicas: Spain's national cancer research center with significantly greater scale and international recognition; overlaps IBSAL's cancer research area as a national incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ibsal_iis
• Facebookfacebook.com/IBSAL.IIS
• LinkedInes.linkedin.com/company/ibsal
• Instagraminstagram.com/ibsal_iis

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto de Investigación Biomédica de Salamanca - IBSAL